Qure AI vs Viz.ai
The same underlying technology, detection on an image, pointed at opposite failures in opposite health systems. Viz.ai detects and then mobilises: its stroke product received the first ever authorization for computer aided triage and notification, and the platform's real work is getting the treating team moving, with outcome evidence measuring care delivery rather than model accuracy. Qure detects where there may be no team to mobilise, holding the broadest chest radiograph regulatory footprint in the market across nine products and deploying into screening programmes and settings where radiologist capacity is thinnest. For a United States health system with an interventional pathway, Viz.ai is the product that shortens time to treatment. For a programme reading large volumes of chest imaging with limited specialist availability, Qure is doing the read itself, and that raises the harder question of what happens to the patients the model misses when nobody else is looking at the film.
- The regulatory breadth across chest radiography is the widest in the market, spanning nine products across radiography and computed tomography, with published device dossiers behind them.
- It is designed for settings where specialist reading capacity is scarce, including public health screening, which is a different deployment problem from reprioritising a hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than managing it, and suits deployments where cross border transfer is not acceptable.
- The authorization history is the deepest in imaging AI, beginning with the first ever clearance for computer aided triage and notification, across more than fifty cleared algorithms spanning imaging, cardiac tracing and echocardiography.
- The evidence measures care delivery rather than detection, which is the harder result to produce and the one that corresponds to patient benefit.
- The communication layer is the product: the finding reaches the treating team automatically, which is what converts a detection into a faster intervention.
Side by Side
| Axis | Q Qure AI |
V Viz.ai |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The consequence of a false negative differs sharply between these deployments and buyers should hold that in mind rather than comparing sensitivity figures directly: in a triage and notification deployment the radiologist still reads every study, while in a capacity constrained screening programme the model's output may be the only read a patient receives.
Prevalence compounds this, since identical operating characteristics produce very different positive predictive values in a screening population than in an acute one. Viz.ai publishes no independent security attestation and no business associate terms. Qure publishes complete device dossiers and comparatively little United States commercial assurance material. Neither publishes pricing.